Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
100 mg | 在庫あり | ¥ 9,500 | |||
200 mg | 在庫あり | ¥ 15,000 | |||
500 mg | 在庫あり | ¥ 32,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,500 |
説明 | Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5. |
ターゲット&IC50 | H+, K+-ATPase:19 nM |
In vitro | The inhibitory activity of Vonoprazan Fumurate was unaffected by ambient pH. The inhibition by Vonoprazan Fumurate was reversible and achieved in a K(+)-competitive manner, quite different from that by lansoprazole. Vonoprazan Fumurate exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner[4]. |
In vivo | Vonoprazan Fumurate, at a dose of 4 mg/kg (as the free base) orally, completely inhibited basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats, and its effect on both was stronger than that of lansoprazole. Vonoprazan Fumurate increased the pH of gastric perfusate to a higher value than did lansoprazole or SCH28080, and the effect of Vonoprazan Fumurate was sustained longer than that of lansoprazole or SCH28080[4]. |
別名 | TAK-438, TAK 438, Vonoprazan Fumurate, TAK438 |
分子量 | 461.46 |
分子式 | C21H20FN3O6S |
CAS No. | 881681-01-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.61 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vonoprazan Fumarate 881681-01-2 Membrane transporter/Ion channel Proton pump peptic potassium TAK-438 secretion reflux competitive TAK 438 proton inhibitor antisecretory disease gastroesophageal Vonoprazan Fumurate inhibit Vonoprazan ulcer GERD blocker acid gastric TAK438 pump P-CAB Proton Pump Inhibitor